



# BioLayer Corporation Limited

Global diagnostics company validates BioLayer technology

**Brisbane, 20 November 2007**

BioLayer Corporation (ASX:BLS) today announced it has met a key milestone in its project with one of the world's largest diagnostics companies.

BioLayer exceeded the deliverable of improved TSH sensitivity of the client company assay by more than 10-fold, a finding confirmed by the US-based company whose identity is protected by a confidential research agreement between the two companies.

TSH or 'thyroid stimulating hormone' is a frequently tested biomarker for the diagnosis of thyroid disease, a treatable condition affecting a million Australians, mainly women, causing either weight loss/hyperactivity or weight gain/lethargy, and other generalized symptoms.

BioLayer's technology has enhanced a client company's test so that it now detects much lower levels of the TSH biomarker in blood than was possible with conventional methods, which is both a commercial advantage to the client as well as being clinically important.

This is the second biomarker assay whose sensitivity BioLayer has improved in as many months; last month the company announced it had developed an ultrasensitive assay for beta amyloid, a putative blood marker for Alzheimer's disease.

*"This is a very satisfying result which has come about through the intense efforts of BioLayer's scientific team in close collaboration with our US partner"* said David Beins, BioLayer's Managing Director and CEO.

The TSH assay is the first of two tests the companies have worked on under the agreement; the second is for PSA or 'prostate specific antigen', a biomarker used in the diagnosis of prostate cancer. Like TSH BioLayer has also improved the assay sensitivity for PSA by more than 10-fold and expects these results to be validated by its US client by January 2008.

*"BioLayer's ground breaking proprietary coatings have now been independently validated by our customers for a number of commercially important biomarkers across different immunoassay platforms"* said David Beins. *"This is a clear sign the company is fast approaching the point where our technology will transition from the lab to the market"*.

**End.**

**BioLayer Corporation Limited ABN 75 070 028 625**  
**Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113**  
**Phone 07 3219 0085 Fax 07 3219 0553 Email [contact@biolayercorp.com](mailto:contact@biolayercorp.com)**  
**Web [www.biolayercorp.com](http://www.biolayercorp.com)**

***About BioLayer:***

**BioLayer Corporation** is an Australian material sciences company specializing in the design and assembly of multi-component coatings for surfaces. BioLayer's proprietary coatings bind, orient and protect proteins such as antibodies, and enhance functionality. This results in dramatically improved immunoassay performance like better sensitivity, and cost savings like batch-to-batch reproducibility. BioLayer applies its coatings to develop proprietary high value ultrasensitive assays in areas of unmet medical need such as tests for neurodegenerative diseases. BioLayer works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit [www.bio-layer.com](http://www.bio-layer.com).

***BioLayer Corporation Limited*** ABN 75 070 028 625  
Unit 4, 26 Brandl Street, Eight Mile Plains QLD 4113  
**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@biolayercorp.com](mailto:contact@biolayercorp.com)  
**Web** [www.biolayercorp.com](http://www.biolayercorp.com)